StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a research report released on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Stock Performance
BLPH opened at $0.05 on Friday. The stock’s 50-day moving average price is $0.05 and its 200 day moving average price is $0.07. Bellerophon Therapeutics has a 12-month low of $0.03 and a 12-month high of $11.15. The firm has a market cap of $666,535.00, a price-to-earnings ratio of -0.06 and a beta of 0.67.
Hedge Funds Weigh In On Bellerophon Therapeutics
Hedge funds have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC acquired a new position in Bellerophon Therapeutics in the 1st quarter valued at about $7,338,000. BlackRock Inc. grew its position in Bellerophon Therapeutics by 34.8% during the second quarter. BlackRock Inc. now owns 129,876 shares of the biotechnology company’s stock worth $90,000 after buying an additional 33,527 shares during the period. Geode Capital Management LLC increased its position in shares of Bellerophon Therapeutics by 49.0% in the first quarter. Geode Capital Management LLC now owns 95,656 shares of the biotechnology company’s stock valued at $755,000 after buying an additional 31,460 shares in the last quarter. HRT Financial LP acquired a new position in Bellerophon Therapeutics during the fourth quarter worth about $25,000. Finally, Renaissance Technologies LLC lifted its position in shares of Bellerophon Therapeutics by 13.0% in the second quarter. Renaissance Technologies LLC now owns 209,399 shares of the biotechnology company’s stock valued at $258,000 after acquiring an additional 24,100 shares in the last quarter. 10.61% of the stock is currently owned by hedge funds and other institutional investors.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Further Reading
- Five stocks we like better than Bellerophon Therapeutics
- Ride Out The Recession With These Dividend Kings
- United Airlines Soars on Earnings Beat
- How to Invest in Biotech Stocks
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Investing In Preferred Stock vs. Common Stock
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
